NASDAQ: TYRA Tyra Biosciences, Inc. 10-Q

Tyra raises $148M, extends runway to H2 2028, advances three Phase 2 trials for dabogratinib

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TYRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.